(CMPS) Compass Pathways - Ratings and Ratios

Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US20451W1018

CMPS: Psilocybin, Therapy, Treatment

COMPASS Pathways plc (NASDAQ:CMPS) is a mental health care company focused on developing innovative treatments for mental health disorders. The company is currently advancing COMP360, a psilocybin-based therapy, through late-stage clinical trials. COMP360 is in Phase III trials for treatment-resistant depression (TRD) and has shown promising results in addressing this debilitating condition. Additionally, the therapy is in Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa, expanding its potential applications in mental health care. Formerly known as COMPASS Rx Limited, the company rebranded as COMPASS Pathways plc in August 2020 and is listed on the NASDAQ stock exchange. Headquartered in London, the company has established a strong presence in both the UK and the US, leveraging its research-driven approach to develop groundbreaking mental health treatments. https://compasspathways.com

Over the next three months, COMPASS Pathways plc (NASDAQ:CMPS) is expected to experience volatility due to its current position below its 20-day, 50-day, and 200-day moving averages (SMA 20: $4.30, SMA 50: $4.08, SMA 200: $5.87). The stocks average trading volume of 1.2 million shares over the last 20 days, combined with its ATR of 0.39, suggests moderate price fluctuations. From a fundamental perspective, the companys negative return on equity (RoE: -74.91) and high price-to-book (P/B: 2.17) ratio indicate significant investment in growth initiatives despite current losses. The lack of forward P/E suggests uncertainty about future profitability. The stock is likely to face resistance at $4.30 and support at $3.50, with potential sideways trading in the near term.

Additional Sources for CMPS Stock

CMPS Stock Overview

Market Cap in USD 347m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Services
IPO / Inception 2020-09-18

CMPS Stock Ratings

Growth 5y -89.9%
Fundamental -40.9%
Dividend 0.0%
Rel. Strength Industry -67.2
Analysts 4.6/5
Fair Price Momentum 1.91 USD
Fair Price DCF -

CMPS Dividends

No Dividends Paid

CMPS Growth Ratios

Growth Correlation 3m -18.8%
Growth Correlation 12m -92%
Growth Correlation 5y -91.9%
CAGR 5y -37.62%
CAGR/Max DD 5y -0.40
Sharpe Ratio 12m -1.09
Alpha -78.27
Beta 1.68
Volatility 68.51%
Current Volume 664.4k
Average Volume 20d 1082.6k
What is the price of CMPS stocks?
As of March 14, 2025, the stock is trading at USD 3.49 with a total of 664,434 shares traded.
Over the past week, the price has changed by -13.18%, over one month by -21.04%, over three months by -17.30% and over the past year by -67.26%.
Is Compass Pathways a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Compass Pathways (NASDAQ:CMPS) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -40.91 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CMPS as of March 2025 is 1.91. This means that CMPS is currently overvalued and has a potential downside of -45.27%.
Is CMPS a buy, sell or hold?
Compass Pathways has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy CMPS.
  • Strong Buy: 6
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CMPS stock price target?
According to ValueRays Forecast Model, CMPS Compass Pathways will be worth about 2.2 in March 2026. The stock is currently trading at 3.49. This means that the stock has a potential downside of -36.68%.
Issuer Forecast Upside
Wallstreet Target Price 17.6 403.2%
Analysts Target Price 21.2 508%
ValueRay Target Price 2.2 -36.7%